Neuroprotective effect of benzylideneacetophenone derivative on the MPTP model of neurodegeneration in mice.
In this study, we investigated the neuroprotective effect of a benzylideneacetophenone derivative, JC3, in a mouse model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's disease (PD). C57BL/6 mice were treated with MPTP (30 mg/kg, i.p.) for 5 consecutive days. JC3 (10 mg/kg, i.p.) treatment was initiated 2 h after the first administration of MPTP and then at 24-h intervals for 3 consecutive days. The mice were sacrificed for analyses 7 days after the last MPTP injection. Immunohistochemistry and Western blot were used to determine the expression levels of tyrosine hydroxylase (TH), dopamine transporter (DAT), OX-42 (a marker of microglial activation), and glial fibrillary acid protein (GFAP, a marker of astrocyte activation) in the substantia nigra (SN) and striatum (ST). The results of these experiments demonstrated that JC3 restored the decreased TH-immunoreactivity (IR) and DAT and JC3 attenuated the increase in OX-42, GFAP, and COX-2 on the SN and ST on day 7 post-MPTP injection. These results suggest that JC3 can be a neuroprotective agent in an MPTP-induced model of PD.
Kang
Jun Mo
JM
Department of Neuroscience and Medical Research Institute, School of Medicine, Ewha Womans University, Seoul, 158-710, Korea.
Jung
Jae-Chul
JC
Kim
Heejeong
H
Lim
Heena
H
Jang
Soyong
S
Oh
Seikwan
S
D000818:Animals; D015153:Blotting, Western; D051546:Cyclooxygenase 2 / Q000096:biosynthesis; D004298:Dopamine / Q000502:physiology; D050483:Dopamine Plasma Membrane Transport Proteins / Q000096:biosynthesis; D005904:Glial Fibrillary Acidic Protein / Q000096:biosynthesis; D007150:Immunohistochemistry; D020267:MPTP Poisoning / Q000473:pathology / Q000517:prevention & control*; D051379:Mice; D017072:Neostriatum / Q000473:pathology; D009474:Neurons / Q000187:drug effects / Q000473:pathology; D018696:Neuroprotective Agents / Q000138:chemical synthesis* / Q000494:pharmacology*; D011427:Propiophenones / Q000138:chemical synthesis* / Q000494:pharmacology*; D013378:Substantia Nigra / Q000473:pathology
C532465:(2E)-3-(4-hydroxy-3-methoxyphenyl) phenylpro-2-1-one; D050483:Dopamine Plasma Membrane Transport Proteins; D005904:Glial Fibrillary Acidic Protein; D018696:Neuroprotective Agents; D011427:Propiophenones; D051546:Cyclooxygenase 2; D004298:Dopamine